FDA Approves Jardiance Tablets To Reduce Cardiovascular Death Risk In Diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Co. (LLY) said that the U.S. Food and Drug Administration has approved a new indication for Jardiance or empagliflozin tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.

from RTT - Biotech http://ift.tt/2fZZ6o9
via IFTTT